3 Results for "

CK2α' subunits

" in MedChemExpress (MCE) Product Catalog:
Products (3)

3 Results for "CK2α' subunits" in MCE Product Catalog:

Cat. No.: HY-184414
Research Areas:  

Cancer

BMS-135-L-Lys is a dual-cation prodrug derived from CK2 inhibitor BMS-135 (HY-181022) through esterification with L-lysine using a secondary alcohol. BMS-135-L-Lys achieves enhanced solubility by maintaining protonation of the ε-amino group of the Lys side chain at intestinal pH. BMS-135-L-Lys is released in situ by intestinal wall esterase from the parent drug, significantly increasing the oral bioavailability of the parent drug and overcoming the non-linear pharmacokinetic problem when the dose of the parent drug is increased. BMS-135-L-Lys can be used in related research on colon cancer and lung cancer .
loading...
    loading...
Cat. No.: HY-184414A
Research Areas:  

Cancer

BMS-135-L-Lys TFA is a dual-cation prodrug derived from CK2 inhibitor BMS-135 (HY-181022) through esterification with L-lysine using a secondary alcohol. BMS-135-L-Lys TFA achieves enhanced solubility by maintaining protonation of the ε-amino group of the Lys side chain at intestinal pH. BMS-135-L-Lys TFA is released in situ by intestinal wall esterase from the parent drug, significantly increasing the oral bioavailability of the parent drug and overcoming the non-linear pharmacokinetic problem when the dose of the parent drug is increased. BMS-135-L-Lys TFA can be used in related research on colon cancer and lung cancer .
loading...
    loading...
Cat. No.: HY-184414B
Research Areas:  

Cancer

BMS-135-L-Lys dihydrochloride is a dual-cation prodrug derived from CK2 inhibitor BMS-135 (HY-181022) through esterification with L-lysine using a secondary alcohol. BMS-135-L-Lys dihydrochloride achieves enhanced solubility by maintaining protonation of the ε-amino group of the Lys side chain at intestinal pH. BMS-135-L-Lys dihydrochloride is released in situ by intestinal wall esterase from the parent drug, significantly increasing the oral bioavailability of the parent drug and overcoming the non-linear pharmacokinetic problem when the dose of the parent drug is increased. BMS-135-L-Lys dihydrochloride can be used in related research on colon cancer and lung cancer .
loading...
    loading...